Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly's diabetes injection Mounjaro and obesity drug Zepbound.
Source: https://www.cnbc.com/2024/06/17/eli-lil ... lp-1s.html
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
